Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.

Abstract

We report here a taxol-bevacizumab-responsive metastatic melanoma case. Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained. 

Topics

Cite this paper

@article{Cao2007ResponseOR, title={Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab.}, author={Mar{\'i}a Gonz{\'a}lez Cao and Santiago Viteri and Cristina Garr{\'a}n and Yago L. Nieto and Jos{\'e} Javier Aristu and Maurizio Ponz and Salvador Mart{\'i}n Algarra}, journal={Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico}, year={2007}, volume={9 2}, pages={119-20} }